thrombocytopenia, a slightly elevated C-reactive protein, while leukocytes were within the normal range. LDH was increased (516 U/L, normal range < 214 U/L). EBV DNA was PCRdetectable in the serum; the quantification revealed a copy number of 9,870/mL. A positron emission tomography/computed tomography (PET/CT) detected fluorodeoxyglucose (FDG) enhancement in the mass of the AV fistula and in several enlarged axillary lymph nodes ( Fig. 1 A, B) . Surgical resection of an aneurysmatic brachial artery with a soft tissue mass . Therefore, a B-cell PTLD-tailored induction protocol was introduced consisting of four initial courses of single-agent anti-CD20 Rituximab immunotherapy followed by another four cycles of a CHOP regimen, achieving excellent long-term survival, largely attributable to reduced toxicity, in Rituximab responders 3 . Given the frail overall condition of our patient at initial presentation, rendering her ineligible for a systemic CHOP-like chemotherapy, we considered here -in analogy to the anti-CD20 Rituximab mono-strategy against B-cell PTLD -an anti-CD30 Brentuximab vedotin (BV) mono-strategy against her T-cell PTLD.
BV is currently approved for the treatment of patients with relapsed/refractory Hodgkin's lymphoma after failure of a high-dose chemotherapy with autologous stem-cell support or two previous lines of polychemotherapy in transplant-ineligible patients, and for patients with systemic ALCL after at least one preceding multi-agent chemotherapy. We found off-label use of BV a particularly appealing option for our patient, since BV is actually an antibodydrug conjugate, designed to deliver relatively high doses of the cytotoxic moiety selectively to their cellular targets while producing limited systemic toxicity. Moreover, BV, unlike
Rituximab, does not rely on immune-mediated effector principles (like antibody-dependent cellular cytotoxicity) that may not be fully operational in immunosuppressed recipients of solid organ transplants.
Three courses of BV (1.8 mg/kg bodyweight) were administered every three week. target. In the case of our patient, a follow up PET/CT 6 months after the first diagnostic PET (Fig 1 E, F) showed a complete remission. Future follow-up will be based on clinical examination, CT scans and potentially PET 7 . A very recent PET/CT after 2 more years still showed no signs of recurrence, and our patient is in good health. 
Figure legends

